Additive cell protective and oxidative stress reducing effects of combined treatment with cromolyn sodium and masitinib on MPTP-induced toxicity in SH-SY5Y neuroblastoma cells
The suppression of oxidative-stress induced neurotoxicity by antioxidants serves as a potential preventive strategy for neurodegenerative diseases. In this study, we aimed to investigate the cell protective and antioxidant effects of masitinib and cromolyn sodium against toxin-induced neurodegenerat...
Gespeichert in:
| Veröffentlicht in: | Chemico-biological interactions 2022-02, Vol.354, p.109808, Article 109808 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 109808 |
| container_title | Chemico-biological interactions |
| container_volume | 354 |
| creator | Goksu Erol, Azize Yasemin Kocanci, Fatma Gonca Demir-Dora, Devrim Uysal, Hilmi |
| description | The suppression of oxidative-stress induced neurotoxicity by antioxidants serves as a potential preventive strategy for neurodegenerative diseases. In this study, we aimed to investigate the cell protective and antioxidant effects of masitinib and cromolyn sodium against toxin-induced neurodegeneration.
First, human neuroblastoma SH-SY5Y cells were differentiated into neuron-like (d)-SH-SY5Y cells. The differentiated cells were confirmed by immuno-staining with anti-PGP9.5 antibody, a neuronal marker. Cell culture groups were formed, and a neurotoxin, 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) was applied on cells followed by masitinib and/or cromolyn sodium treatments. Survival rate of cells were detected by MTT assay. Anti-inflammatory Transforming Growth Factor-β1 (TGF-β1) and nitric oxide (NO) levels and total oxidant and antioxidant capacities (TOC and TAC) in cell conditioned media (CM) were measured. Morphological analysis and apoptotic nuclear assessment of cells were also noted.
When (d)-SH-SY5Y cells were exposed to neurotoxin, cell viability rates of these cells were found to be decreased in a concentration-dependent manner. CM of toxin applied group displayed higher levels of TOC/TAC ratios and NO levels compared to control (p |
| doi_str_mv | 10.1016/j.cbi.2022.109808 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2618908371</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0009279722000138</els_id><sourcerecordid>2618908371</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-8a3696a10c0c5db3affbb267fb000c085fc2be1eba5de05592cecb132c60215d3</originalsourceid><addsrcrecordid>eNp9UctuFDEQtBCILIEP4IJ85DKL7YnnIU5RFAhSEJESDjlZfvRAr8Z2sD2B_ar8Yry7gSOnVklV1d1VhLzlbM0Z7z5s1tbgWjAhKh4HNjwjKz70oun7oXtOVoyxsRH92B-RVzlvKmTihL0kR61krJfiZEUeTp3DgvdALcwzvUuxgN1jHRyNf9DpPcolQc40gVsshh8UpqnyMo0TtdEbDOBopejiIRT6G8tPalP0cd4GmqPDxe8Nvc51W0BDY6Bfr26uGgzVcSeuuyyWLcVAry-a61t5SwMsKZpZ5xK93h-YX5MXk54zvHmax-T7p_Obs4vm8tvnL2enl41tZVuaQbfd2GnOLLPSmVZPkzGi6ydTM7BskJMVBjgYLR0wKUdhwRreCtsxwaVrj8n7g29N5NcCuSiPeXeBDhCXrETHh5ENbc8rlR-o9eGcE0zqLqHXaas4U7ue1EbVntSuJ3XoqWrePdkvxoP7p_hbTCV8PBCgPnmPkFS2CKEmhakGr1zE_9g_Arb7p2g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2618908371</pqid></control><display><type>article</type><title>Additive cell protective and oxidative stress reducing effects of combined treatment with cromolyn sodium and masitinib on MPTP-induced toxicity in SH-SY5Y neuroblastoma cells</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Goksu Erol, Azize Yasemin ; Kocanci, Fatma Gonca ; Demir-Dora, Devrim ; Uysal, Hilmi</creator><creatorcontrib>Goksu Erol, Azize Yasemin ; Kocanci, Fatma Gonca ; Demir-Dora, Devrim ; Uysal, Hilmi</creatorcontrib><description>The suppression of oxidative-stress induced neurotoxicity by antioxidants serves as a potential preventive strategy for neurodegenerative diseases. In this study, we aimed to investigate the cell protective and antioxidant effects of masitinib and cromolyn sodium against toxin-induced neurodegeneration.
First, human neuroblastoma SH-SY5Y cells were differentiated into neuron-like (d)-SH-SY5Y cells. The differentiated cells were confirmed by immuno-staining with anti-PGP9.5 antibody, a neuronal marker. Cell culture groups were formed, and a neurotoxin, 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) was applied on cells followed by masitinib and/or cromolyn sodium treatments. Survival rate of cells were detected by MTT assay. Anti-inflammatory Transforming Growth Factor-β1 (TGF-β1) and nitric oxide (NO) levels and total oxidant and antioxidant capacities (TOC and TAC) in cell conditioned media (CM) were measured. Morphological analysis and apoptotic nuclear assessment of cells were also noted.
When (d)-SH-SY5Y cells were exposed to neurotoxin, cell viability rates of these cells were found to be decreased in a concentration-dependent manner. CM of toxin applied group displayed higher levels of TOC/TAC ratios and NO levels compared to control (p < 0.01). Both masitinib and cromolyn sodium protected cells from toxin-induced cell death as revealed by ameliorated rates of viability, reversed toxin-induced elevation of TOC/TAC ratios, and decreased NO levels in their CM (p < 0.01). Combined treatment significantly reduced TOC/TAC ratios and NO levels more effectively compared to mono-treatments. Both drugs also increased TGF-β1 levels significantly in cell CM. When these agents were tested for therapeutic effects against toxin-induced cell degeneration, better viability results were obtained by both masitinib and cromolyn sodium treatment, with significantly better amelioration provided by combined application of these drugs (p < 0.01).
This study demonstrated new findings that combined treatment with cromolyn sodium, an FDA-approved drug of asthma, and masitinib, an orally administered drug with a low toxicity, exert neuroprotective and additive therapeutic effects. We propose that combination therapy of masitinib and cromolyn sodium may represent an innovative treatment in neurodegenerative diseases. Combination therapy may be more advantageous that it enables combined application of lower doses of both drugs, providing less side effects.
•Masitinib, cromolyn sodium and their combined treatment protect neuronal cells against MPTP induced toxicity.•Masitinib, cromolyn sodium and their combined treatment mitigates MPTP-induced oxidative stress.•Combined treatment of masitinib and cromolyn sodium exerts additive neuroprotective/therapeutic effects.</description><identifier>ISSN: 0009-2797</identifier><identifier>ISSN: 1872-7786</identifier><identifier>EISSN: 1872-7786</identifier><identifier>DOI: 10.1016/j.cbi.2022.109808</identifier><identifier>PMID: 35007524</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>1-Methyl-4-phenylpyridinium - toxicity ; Antioxidants - pharmacology ; Apoptosis - drug effects ; Benzamides - pharmacology ; Cell Line, Tumor ; Cell Survival - drug effects ; Cromolyn sodium ; Cromolyn Sodium - pharmacology ; Humans ; Masitinib ; Neuroblastoma - drug therapy ; Neuroblastoma - metabolism ; Neuroblastoma - pathology ; Neurodegeneration ; Neuroprotective Agents - pharmacology ; Nitric Oxide - metabolism ; Oxidative stress ; Oxidative Stress - drug effects ; Piperidines - pharmacology ; Pyridines - pharmacology ; SH-SY5Y Cells ; Thiazoles - pharmacology ; Transforming Growth Factor beta1 - metabolism ; Transforming growth Factor-β1</subject><ispartof>Chemico-biological interactions, 2022-02, Vol.354, p.109808, Article 109808</ispartof><rights>2022 Elsevier B.V.</rights><rights>Copyright © 2022 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-8a3696a10c0c5db3affbb267fb000c085fc2be1eba5de05592cecb132c60215d3</citedby><cites>FETCH-LOGICAL-c353t-8a3696a10c0c5db3affbb267fb000c085fc2be1eba5de05592cecb132c60215d3</cites><orcidid>0000-0002-6610-2507</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cbi.2022.109808$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35007524$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goksu Erol, Azize Yasemin</creatorcontrib><creatorcontrib>Kocanci, Fatma Gonca</creatorcontrib><creatorcontrib>Demir-Dora, Devrim</creatorcontrib><creatorcontrib>Uysal, Hilmi</creatorcontrib><title>Additive cell protective and oxidative stress reducing effects of combined treatment with cromolyn sodium and masitinib on MPTP-induced toxicity in SH-SY5Y neuroblastoma cells</title><title>Chemico-biological interactions</title><addtitle>Chem Biol Interact</addtitle><description>The suppression of oxidative-stress induced neurotoxicity by antioxidants serves as a potential preventive strategy for neurodegenerative diseases. In this study, we aimed to investigate the cell protective and antioxidant effects of masitinib and cromolyn sodium against toxin-induced neurodegeneration.
First, human neuroblastoma SH-SY5Y cells were differentiated into neuron-like (d)-SH-SY5Y cells. The differentiated cells were confirmed by immuno-staining with anti-PGP9.5 antibody, a neuronal marker. Cell culture groups were formed, and a neurotoxin, 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) was applied on cells followed by masitinib and/or cromolyn sodium treatments. Survival rate of cells were detected by MTT assay. Anti-inflammatory Transforming Growth Factor-β1 (TGF-β1) and nitric oxide (NO) levels and total oxidant and antioxidant capacities (TOC and TAC) in cell conditioned media (CM) were measured. Morphological analysis and apoptotic nuclear assessment of cells were also noted.
When (d)-SH-SY5Y cells were exposed to neurotoxin, cell viability rates of these cells were found to be decreased in a concentration-dependent manner. CM of toxin applied group displayed higher levels of TOC/TAC ratios and NO levels compared to control (p < 0.01). Both masitinib and cromolyn sodium protected cells from toxin-induced cell death as revealed by ameliorated rates of viability, reversed toxin-induced elevation of TOC/TAC ratios, and decreased NO levels in their CM (p < 0.01). Combined treatment significantly reduced TOC/TAC ratios and NO levels more effectively compared to mono-treatments. Both drugs also increased TGF-β1 levels significantly in cell CM. When these agents were tested for therapeutic effects against toxin-induced cell degeneration, better viability results were obtained by both masitinib and cromolyn sodium treatment, with significantly better amelioration provided by combined application of these drugs (p < 0.01).
This study demonstrated new findings that combined treatment with cromolyn sodium, an FDA-approved drug of asthma, and masitinib, an orally administered drug with a low toxicity, exert neuroprotective and additive therapeutic effects. We propose that combination therapy of masitinib and cromolyn sodium may represent an innovative treatment in neurodegenerative diseases. Combination therapy may be more advantageous that it enables combined application of lower doses of both drugs, providing less side effects.
•Masitinib, cromolyn sodium and their combined treatment protect neuronal cells against MPTP induced toxicity.•Masitinib, cromolyn sodium and their combined treatment mitigates MPTP-induced oxidative stress.•Combined treatment of masitinib and cromolyn sodium exerts additive neuroprotective/therapeutic effects.</description><subject>1-Methyl-4-phenylpyridinium - toxicity</subject><subject>Antioxidants - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>Benzamides - pharmacology</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>Cromolyn sodium</subject><subject>Cromolyn Sodium - pharmacology</subject><subject>Humans</subject><subject>Masitinib</subject><subject>Neuroblastoma - drug therapy</subject><subject>Neuroblastoma - metabolism</subject><subject>Neuroblastoma - pathology</subject><subject>Neurodegeneration</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>Nitric Oxide - metabolism</subject><subject>Oxidative stress</subject><subject>Oxidative Stress - drug effects</subject><subject>Piperidines - pharmacology</subject><subject>Pyridines - pharmacology</subject><subject>SH-SY5Y Cells</subject><subject>Thiazoles - pharmacology</subject><subject>Transforming Growth Factor beta1 - metabolism</subject><subject>Transforming growth Factor-β1</subject><issn>0009-2797</issn><issn>1872-7786</issn><issn>1872-7786</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UctuFDEQtBCILIEP4IJ85DKL7YnnIU5RFAhSEJESDjlZfvRAr8Z2sD2B_ar8Yry7gSOnVklV1d1VhLzlbM0Z7z5s1tbgWjAhKh4HNjwjKz70oun7oXtOVoyxsRH92B-RVzlvKmTihL0kR61krJfiZEUeTp3DgvdALcwzvUuxgN1jHRyNf9DpPcolQc40gVsshh8UpqnyMo0TtdEbDOBopejiIRT6G8tPalP0cd4GmqPDxe8Nvc51W0BDY6Bfr26uGgzVcSeuuyyWLcVAry-a61t5SwMsKZpZ5xK93h-YX5MXk54zvHmax-T7p_Obs4vm8tvnL2enl41tZVuaQbfd2GnOLLPSmVZPkzGi6ydTM7BskJMVBjgYLR0wKUdhwRreCtsxwaVrj8n7g29N5NcCuSiPeXeBDhCXrETHh5ENbc8rlR-o9eGcE0zqLqHXaas4U7ue1EbVntSuJ3XoqWrePdkvxoP7p_hbTCV8PBCgPnmPkFS2CKEmhakGr1zE_9g_Arb7p2g</recordid><startdate>20220225</startdate><enddate>20220225</enddate><creator>Goksu Erol, Azize Yasemin</creator><creator>Kocanci, Fatma Gonca</creator><creator>Demir-Dora, Devrim</creator><creator>Uysal, Hilmi</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6610-2507</orcidid></search><sort><creationdate>20220225</creationdate><title>Additive cell protective and oxidative stress reducing effects of combined treatment with cromolyn sodium and masitinib on MPTP-induced toxicity in SH-SY5Y neuroblastoma cells</title><author>Goksu Erol, Azize Yasemin ; Kocanci, Fatma Gonca ; Demir-Dora, Devrim ; Uysal, Hilmi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-8a3696a10c0c5db3affbb267fb000c085fc2be1eba5de05592cecb132c60215d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>1-Methyl-4-phenylpyridinium - toxicity</topic><topic>Antioxidants - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>Benzamides - pharmacology</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>Cromolyn sodium</topic><topic>Cromolyn Sodium - pharmacology</topic><topic>Humans</topic><topic>Masitinib</topic><topic>Neuroblastoma - drug therapy</topic><topic>Neuroblastoma - metabolism</topic><topic>Neuroblastoma - pathology</topic><topic>Neurodegeneration</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>Nitric Oxide - metabolism</topic><topic>Oxidative stress</topic><topic>Oxidative Stress - drug effects</topic><topic>Piperidines - pharmacology</topic><topic>Pyridines - pharmacology</topic><topic>SH-SY5Y Cells</topic><topic>Thiazoles - pharmacology</topic><topic>Transforming Growth Factor beta1 - metabolism</topic><topic>Transforming growth Factor-β1</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goksu Erol, Azize Yasemin</creatorcontrib><creatorcontrib>Kocanci, Fatma Gonca</creatorcontrib><creatorcontrib>Demir-Dora, Devrim</creatorcontrib><creatorcontrib>Uysal, Hilmi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chemico-biological interactions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goksu Erol, Azize Yasemin</au><au>Kocanci, Fatma Gonca</au><au>Demir-Dora, Devrim</au><au>Uysal, Hilmi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Additive cell protective and oxidative stress reducing effects of combined treatment with cromolyn sodium and masitinib on MPTP-induced toxicity in SH-SY5Y neuroblastoma cells</atitle><jtitle>Chemico-biological interactions</jtitle><addtitle>Chem Biol Interact</addtitle><date>2022-02-25</date><risdate>2022</risdate><volume>354</volume><spage>109808</spage><pages>109808-</pages><artnum>109808</artnum><issn>0009-2797</issn><issn>1872-7786</issn><eissn>1872-7786</eissn><abstract>The suppression of oxidative-stress induced neurotoxicity by antioxidants serves as a potential preventive strategy for neurodegenerative diseases. In this study, we aimed to investigate the cell protective and antioxidant effects of masitinib and cromolyn sodium against toxin-induced neurodegeneration.
First, human neuroblastoma SH-SY5Y cells were differentiated into neuron-like (d)-SH-SY5Y cells. The differentiated cells were confirmed by immuno-staining with anti-PGP9.5 antibody, a neuronal marker. Cell culture groups were formed, and a neurotoxin, 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) was applied on cells followed by masitinib and/or cromolyn sodium treatments. Survival rate of cells were detected by MTT assay. Anti-inflammatory Transforming Growth Factor-β1 (TGF-β1) and nitric oxide (NO) levels and total oxidant and antioxidant capacities (TOC and TAC) in cell conditioned media (CM) were measured. Morphological analysis and apoptotic nuclear assessment of cells were also noted.
When (d)-SH-SY5Y cells were exposed to neurotoxin, cell viability rates of these cells were found to be decreased in a concentration-dependent manner. CM of toxin applied group displayed higher levels of TOC/TAC ratios and NO levels compared to control (p < 0.01). Both masitinib and cromolyn sodium protected cells from toxin-induced cell death as revealed by ameliorated rates of viability, reversed toxin-induced elevation of TOC/TAC ratios, and decreased NO levels in their CM (p < 0.01). Combined treatment significantly reduced TOC/TAC ratios and NO levels more effectively compared to mono-treatments. Both drugs also increased TGF-β1 levels significantly in cell CM. When these agents were tested for therapeutic effects against toxin-induced cell degeneration, better viability results were obtained by both masitinib and cromolyn sodium treatment, with significantly better amelioration provided by combined application of these drugs (p < 0.01).
This study demonstrated new findings that combined treatment with cromolyn sodium, an FDA-approved drug of asthma, and masitinib, an orally administered drug with a low toxicity, exert neuroprotective and additive therapeutic effects. We propose that combination therapy of masitinib and cromolyn sodium may represent an innovative treatment in neurodegenerative diseases. Combination therapy may be more advantageous that it enables combined application of lower doses of both drugs, providing less side effects.
•Masitinib, cromolyn sodium and their combined treatment protect neuronal cells against MPTP induced toxicity.•Masitinib, cromolyn sodium and their combined treatment mitigates MPTP-induced oxidative stress.•Combined treatment of masitinib and cromolyn sodium exerts additive neuroprotective/therapeutic effects.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>35007524</pmid><doi>10.1016/j.cbi.2022.109808</doi><orcidid>https://orcid.org/0000-0002-6610-2507</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-2797 |
| ispartof | Chemico-biological interactions, 2022-02, Vol.354, p.109808, Article 109808 |
| issn | 0009-2797 1872-7786 1872-7786 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2618908371 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | 1-Methyl-4-phenylpyridinium - toxicity Antioxidants - pharmacology Apoptosis - drug effects Benzamides - pharmacology Cell Line, Tumor Cell Survival - drug effects Cromolyn sodium Cromolyn Sodium - pharmacology Humans Masitinib Neuroblastoma - drug therapy Neuroblastoma - metabolism Neuroblastoma - pathology Neurodegeneration Neuroprotective Agents - pharmacology Nitric Oxide - metabolism Oxidative stress Oxidative Stress - drug effects Piperidines - pharmacology Pyridines - pharmacology SH-SY5Y Cells Thiazoles - pharmacology Transforming Growth Factor beta1 - metabolism Transforming growth Factor-β1 |
| title | Additive cell protective and oxidative stress reducing effects of combined treatment with cromolyn sodium and masitinib on MPTP-induced toxicity in SH-SY5Y neuroblastoma cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T18%3A23%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Additive%20cell%20protective%20and%20oxidative%20stress%20reducing%20effects%20of%20combined%20treatment%20with%20cromolyn%20sodium%20and%20masitinib%20on%20MPTP-induced%20toxicity%20in%20SH-SY5Y%20neuroblastoma%20cells&rft.jtitle=Chemico-biological%20interactions&rft.au=Goksu%20Erol,%20Azize%20Yasemin&rft.date=2022-02-25&rft.volume=354&rft.spage=109808&rft.pages=109808-&rft.artnum=109808&rft.issn=0009-2797&rft.eissn=1872-7786&rft_id=info:doi/10.1016/j.cbi.2022.109808&rft_dat=%3Cproquest_cross%3E2618908371%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2618908371&rft_id=info:pmid/35007524&rft_els_id=S0009279722000138&rfr_iscdi=true |